Navigating the 2026 Biennial MoCRA Facility Registration Renewal Cycle

The Biennial Renewal Obligation Under MoCRA

The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) fundamentally altered the compliance landscape for cosmetic manufacturers and processors by introducing, for the first time, a mandatory facility registration regime administered by the U.S. Food and Drug Administration. Under MoCRA, facilities engaged in manufacturing or processing cosmetic products for distribution in the United States must register with FDA and, critically, must renew that registration biennially—every two years.

As the calendar turns toward 2026, the industry confronts its first true test of this renewal cycle. The initial registration wave, driven by MoCRA's original compliance deadlines, established baseline data for tens of thousands of facilities. The 2026 renewal is not a mere formality. It is the mechanism by which FDA will begin to assess the accuracy, currency, and reliability of the facility data it now holds—and the first meaningful opportunity for the agency to identify discrepancies, lapses, or noncompliance across the regulated population.

For general counsel, compliance officers, and regulatory affairs leadership, this renewal window should be treated as a substantive compliance checkpoint, not an administrative afterthought.

Why the 2026 Cycle Carries Elevated Risk

Several factors converge to make this particular renewal period more consequential than a routine biennial filing might otherwise suggest.

• First cycle precedent. How FDA handles late, incomplete, or inaccurate renewals in 2026 will likely shape enforcement posture and industry expectations for years to come. Facilities that treat this cycle casually risk becoming examples in whatever enforcement approach the agency ultimately adopts.
• Data drift since original registration. In the intervening period since initial MoCRA registrations were filed, many facilities have experienced changes in ownership, physical location, contract manufacturing relationships, product lines, or responsible person designations. Registration data that was accurate at initial filing may now be stale.
• Heightened FDA scrutiny of cosmetic safety. MoCRA emerged from a broader legislative effort to modernize cosmetic oversight, including new adverse event reporting and safety substantiation requirements. Facility registration data intersects with these other compliance obligations, meaning inaccuracies in registration can complicate or undermine a company's broader regulatory posture.
• Interconnected compliance obligations. Registration renewal does not exist in isolation. It is tied to product listing obligations, responsible person designations, and the agency's broader enforcement toolkit, including its authority to suspend a facility's registration in specified circumstances.

Core Data Points Requiring Verification

Before the renewal window closes, facilities should conduct a rigorous internal audit of the information on file with FDA. Key data points warranting verification include:

• Facility identification information, including legal entity name, physical address, and any FDA-assigned facility registration number.
• Ownership and corporate structure, particularly where mergers, acquisitions, divestitures, or corporate reorganizations have occurred since the original registration.
• Contract manufacturing arrangements, including whether the registrant remains the appropriate party responsible for registration given current sourcing and production relationships.
• Responsible person designations, ensuring the entity identified as the "responsible person" under MoCRA remains accurate and that contact information is current.
• Product category and formulation changes that may affect whether registration information filed previously still reflects current operations.
• Facility operational status, confirming that facilities listed as active are, in fact, still manufacturing or processing cosmetic products, and that any closed, sold, or repurposed facilities are properly reflected.

Companies with multiple facilities, complex supply chains, or recent transactional activity should treat this audit as a cross-functional exercise involving regulatory affairs, legal, operations, and, where relevant, transaction counsel who handled any recent M&A activity.

Enforcement Risk and the Consequences of Inaccuracy

MoCRA grants FDA meaningful enforcement tools tied directly to registration compliance. Facilities that fail to register, or that maintain inaccurate registration information, expose themselves to a range of regulatory consequences, including the possibility that FDA may suspend a facility's registration where the agency determines that a cosmetic product manufactured or processed at the facility has a reasonable probability of causing serious adverse health consequences and other conditions specified under the statute are met.

Beyond formal suspension authority, inaccurate or lapsed registration data can generate collateral consequences:

• Complications during FDA facility inspections, where inspectors rely on registration data to confirm facility scope and operations.
• Difficulty defending against enforcement actions if a company's own records conflict with FDA's registration database.
• Reputational and commercial risk, as retail partners, distributors, and international counterparts increasingly expect verifiable MoCRA compliance as a condition of doing business.
• Potential complications in due diligence for future corporate transactions, where buyers and investors now routinely scrutinize MoCRA registration status as part of regulatory diligence.

Practical Recommendations for the 2026 Cycle

Given the stakes, we recommend that cosmetic manufacturers and processors take the following steps well in advance of applicable renewal deadlines:

• Initiate an internal registration audit now. Do not wait until the renewal window is imminent to discover that facility data is outdated.
• Designate clear internal ownership of the renewal process, with accountability spanning regulatory, legal, and operational stakeholders.
• Reconcile registration data against corporate records, including recent M&A documentation, facility lease or ownership changes, and updated organizational charts.
• Document the audit and renewal process, creating a defensible internal record demonstrating diligence in maintaining accurate registration data.
• Monitor FDA guidance closely, as the agency continues to issue interpretive guidance and may refine expectations as this first renewal cycle unfolds.

Positioning for Ongoing Regulatory Management

The 2026 renewal cycle marks a transition point: MoCRA compliance is shifting from a one-time registration exercise to an ongoing regulatory management discipline. Companies that build durable internal processes now—rather than treating each biennial renewal as an isolated event—will be far better positioned to manage risk, satisfy FDA expectations, and maintain credibility with commercial partners as the cosmetics regulatory landscape continues to mature.

Anthony Girand Law advises cosmetic manufacturers, processors, and their corporate stakeholders on MoCRA compliance strategy, including registration audits, renewal preparation, and enforcement risk management. Companies navigating this first biennial renewal cycle should treat the process as an opportunity to strengthen their regulatory foundation, not merely satisfy a filing deadline.